BlackRock (BLK) - FREE Research Report

Fairbairn Robert W who is Senior Managing Director at BlackRock sold 6,650 shares at $303.03 on Nov. 19, 2013. Following this transaction, the Senior Managing Director owned 76,754 shares meaning that the stake was reduced by 7.97% with the 6,650 share transaction.

The shares most recently traded at $302.90, down $0.13, or 0.04% since the insider transaction. Historical insider transactions for BlackRock go as follows:

  • 24-Week # shares sold: 52,616

The average volume for BlackRock has been 672,300 shares per day over the past 30 days. BlackRock has a market cap of $50.8 billion and is part of the financial sector and financial services industry. Shares are up 47.04% year to date as of the close of trading on Tuesday.

BlackRock, Inc. is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors. The stock currently has a dividend yield of 2.21%. The company has a P/E ratio of 19.1. Currently there are 6 analysts that rate BlackRock a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BLK - FREE

TheStreet Quant Ratings rates BlackRock as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full BlackRock Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Facebook and Snap Have One Issue That Will Have to Be Solved: Peter Bonfield

10 Biggest Takeaways from Apple's iPhone X Event

Google Pixel 2 Debuting October 4, FYI Apple

The iPhone X Highlights This Overlooked Strength of Apple's

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round